{"id":37182,"date":"2025-10-28T22:03:38","date_gmt":"2025-10-28T15:03:38","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=37182"},"modified":"2025-10-28T22:03:38","modified_gmt":"2025-10-28T15:03:38","slug":"noul-supplies-ai-diagnostic-platform-milab-to-charite-europes-leading-university-hospital","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=37182","title":{"rendered":"Noul Supplies AI Diagnostic Platform miLab\u2122 to Charit\u00e9, Europe&#8217;s Leading University Hospital"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1854227\/Noul_logo1_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Prestigious Nobel Prize\u2013winning institution confirms adoption of\u00a0miLab\u2122 following clinical evaluation<\/li>\n<li>&#8220;A milestone signaling broader adoption in advanced global healthcare markets&#8221;<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">YONGIN, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Noul Co., Ltd.(CEO <span class=\"xn-person\">David Lim<\/span>), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab\u2122 MAL to Charit\u00e9 \u2013 Universit\u00e4tsmedizin <span class=\"xn-location\">Berlin, Germany&#8217;s<\/span> largest and most prestigious university hospital.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>Founded over 300 years ago, Charit\u00e9 is ranked No. 1 in <span class=\"xn-location\">Germany<\/span> and No. 7 worldwide, and has produced 11 Nobel laureates in Physiology or Medicine, including <span class=\"xn-person\">Robert Koch<\/span>. The institution leads pioneering research across numerous medical fields and operates four campuses across <span class=\"xn-location\">Berlin<\/span>, with over 3,500 hospital beds and 4,000 medical and research professionals.<\/p>\n<p>Noul has been conducting evaluations of its miLab platform with Charit\u00e9 University Hospital since earlier this year, and the platform has demonstrated satisfactory performance and utility in real clinical settings, leading to the current supply agreement. The adoption of miLab has reduced sample preparation and reading times, preventing diagnostic delays. Additionally, the cost per diagnostic test has been significantly lowered, and the platform&#8217;s high usability minimizes training time, enabling efficient reallocation of human resources.<\/p>\n<p><span class=\"xn-person\">David Lim<\/span>, CEO of Noul stated &#8220;Supplying our miLab platform to a world-renowned institution such as Charit\u00e9 University Hospital marks a significant step in our expansion into advanced healthcare markets.&#8221; He added &#8220;This achievement validates the global competitiveness of Noul&#8217;s technology and establishes global trust in our AI diagnostic solution, which combines both accuracy and efficiency. We anticipate that this will enhance brand recognition and facilitate broader adoption of our platform in leading healthcare markets, including <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">North America<\/span>.&#8221;<\/p>\n<p>With this deployment, miLab will be installed in the laboratory of the Institute for International Health of Charit<span>\u00e9<\/span>, an important center for malaria surveillance. By providing rapid and accurate diagnostics, miLab is poised to play a pivotal role in malaria management and in responding to imported tropical diseases.<\/p>\n<p>Noul&#8217;s miLab\u2122 is an innovative point-of-care diagnostic platform that automates the entire process of blood and cancer diagnostics traditionally performed under manual microscopy. The system fully integrates sample preparation, digital imaging, and AI analysis, enabling clinicians to make faster and more consistent diagnostic decisions. Its automation minimizes human variability, ensures standardized diagnostic quality, and improves overall workflow efficiency\u2014delivering significant value even in advanced medical environments.<\/p>\n<p>Since 2024, Noul has been supplying miLab\u2122 MAL (Malaria) and miLab\u2122 BCM (Blood Count and Morphology) through <span class=\"xn-location\">Germany&#8217;s<\/span> largest laboratory network, Limbach Group, and via a local distributor in <span class=\"xn-location\">Italy<\/span>. Starting from the fourth quarter of 2025, the company expects to expand deliveries to major European countries, including <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-location\">Italy<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span>. By securing this global top-tier reference, Noul aims to strengthen strategic partnerships and accelerate growth across key global markets, including <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p><b>[About Noul Co., Ltd.]<\/b><\/p>\n<p><b>&#8220;Enabling blood and cancer diagnostics anywhere in the world with AI.&#8221;<\/b><\/p>\n<p>Founded in <span class=\"xn-chron\">December 2015<\/span>, Noul (376930.KQ) is an on-device AI healthcare company with a mission to explore global challenges that threaten human health and life, discover novel solutions, and realize those possibilities. Noul has commercialized the world&#8217;s first AI-powered diagnostic lab, miLab\u2122, through convergence of AI, biotechnology, and compact robotics.<\/p>\n<p>The miLab\u2122 Platform is the only solution that fully automates the microscopic diagnostic process\u2014from sample preparation to AI-based image analysis\u2014delivering lab-grade blood and cancer diagnostics at the point of care. Within 15 minutes, miLab\u2122 produces precise results even in low-resource settings.<\/p>\n<p>In 2022, miLab\u2122 was described in a UNITAID report as <i>&#8220;The most advanced digital microscope and fully integrated bench-top platform&#8221;<\/i> for malaria diagnostics. It is now deployed in 28 countries, used by pharmaceutical companies, hospitals, labs, and public health institutions worldwide.<\/p>\n<p>With strong clinical validation and proven performance, Noul is rapidly expanding its market presence, especially in malaria, blood analysis, and cervical cancer diagnostics. The company&#8217;s vision is to make a meaningful impact on the lives of 1 billion people worldwide through accessible, innovative diagnostic technologies.<\/p>\n<p>Website: <u><a href=\"https:\/\/noul.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/noul.com<\/a><\/u><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1854227\/Noul_logo1_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Prestigious Nobel Prize\u2013winning institution confirms adoption of\u00a0miLab\u2122 following clinical evaluation<\/li>\n<li>&#8220;A milestone signaling broader adoption in advanced global healthcare markets&#8221;<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">YONGIN, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Noul Co., Ltd.(CEO <span class=\"xn-person\">David Lim<\/span>), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab\u2122 MAL to Charit\u00e9 \u2013 Universit\u00e4tsmedizin <span class=\"xn-location\">Berlin, Germany&#8217;s<\/span> largest and most prestigious university hospital.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>Founded over 300 years ago, Charit\u00e9 is ranked No. 1 in <span class=\"xn-location\">Germany<\/span> and No. 7 worldwide, and has produced 11 Nobel laureates in Physiology or Medicine, including <span class=\"xn-person\">Robert Koch<\/span>. The institution leads pioneering research across numerous medical fields and operates four campuses across <span class=\"xn-location\">Berlin<\/span>, with over 3,500 hospital beds and 4,000 medical and research professionals.<\/p>\n<p>Noul has been conducting evaluations of its miLab platform with Charit\u00e9 University Hospital since earlier this year, and the platform has demonstrated satisfactory performance and utility in real clinical settings, leading to the current supply agreement. The adoption of miLab has reduced sample preparation and reading times, preventing diagnostic delays. Additionally, the cost per diagnostic test has been significantly lowered, and the platform&#8217;s high usability minimizes training time, enabling efficient reallocation of human resources.<\/p>\n<p><span class=\"xn-person\">David Lim<\/span>, CEO of Noul stated &#8220;Supplying our miLab platform to a world-renowned institution such as Charit\u00e9 University Hospital marks a significant step in our expansion into advanced healthcare markets.&#8221; He added &#8220;This achievement validates the global competitiveness of Noul&#8217;s technology and establishes global trust in our AI diagnostic solution, which combines both accuracy and efficiency. We anticipate that this will enhance brand recognition and facilitate broader adoption of our platform in leading healthcare markets, including <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">North America<\/span>.&#8221;<\/p>\n<p>With this deployment, miLab will be installed in the laboratory of the Institute for International Health of Charit<span>\u00e9<\/span>, an important center for malaria surveillance. By providing rapid and accurate diagnostics, miLab is poised to play a pivotal role in malaria management and in responding to imported tropical diseases.<\/p>\n<p>Noul&#8217;s miLab\u2122 is an innovative point-of-care diagnostic platform that automates the entire process of blood and cancer diagnostics traditionally performed under manual microscopy. The system fully integrates sample preparation, digital imaging, and AI analysis, enabling clinicians to make faster and more consistent diagnostic decisions. Its automation minimizes human variability, ensures standardized diagnostic quality, and improves overall workflow efficiency\u2014delivering significant value even in advanced medical environments.<\/p>\n<p>Since 2024, Noul has been supplying miLab\u2122 MAL (Malaria) and miLab\u2122 BCM (Blood Count and Morphology) through <span class=\"xn-location\">Germany&#8217;s<\/span> largest laboratory network, Limbach Group, and via a local distributor in <span class=\"xn-location\">Italy<\/span>. Starting from the fourth quarter of 2025, the company expects to expand deliveries to major European countries, including <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-location\">Italy<\/span>, <span class=\"xn-location\">Switzerland<\/span>, and <span class=\"xn-location\">France<\/span>. By securing this global top-tier reference, Noul aims to strengthen strategic partnerships and accelerate growth across key global markets, including <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p><b>[About Noul Co., Ltd.]<\/b><\/p>\n<p><b>&#8220;Enabling blood and cancer diagnostics anywhere in the world with AI.&#8221;<\/b><\/p>\n<p>Founded in <span class=\"xn-chron\">December 2015<\/span>, Noul (376930.KQ) is an on-device AI healthcare company with a mission to explore global challenges that threaten human health and life, discover novel solutions, and realize those possibilities. Noul has commercialized the world&#8217;s first AI-powered diagnostic lab, miLab\u2122, through convergence of AI, biotechnology, and compact robotics.<\/p>\n<p>The miLab\u2122 Platform is the only solution that fully automates the microscopic diagnostic process\u2014from sample preparation to AI-based image analysis\u2014delivering lab-grade blood and cancer diagnostics at the point of care. Within 15 minutes, miLab\u2122 produces precise results even in low-resource settings.<\/p>\n<p>In 2022, miLab\u2122 was described in a UNITAID report as <i>&#8220;The most advanced digital microscope and fully integrated bench-top platform&#8221;<\/i> for malaria diagnostics. It is now deployed in 28 countries, used by pharmaceutical companies, hospitals, labs, and public health institutions worldwide.<\/p>\n<p>With strong clinical validation and proven performance, Noul is rapidly expanding its market presence, especially in malaria, blood analysis, and cervical cancer diagnostics. The company&#8217;s vision is to make a meaningful impact on the lives of 1 billion people worldwide through accessible, innovative diagnostic technologies.<\/p>\n<p>Website: <u><a href=\"https:\/\/noul.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/noul.com<\/a><\/u><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37182"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37182\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}